Suppr超能文献

309例接受射频消融治疗的结直肠癌肝转移患者的5年生存率。

Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation.

作者信息

Gillams A R, Lees W R

机构信息

University College Hospital and University College London Medical School, London, UK.

出版信息

Eur Radiol. 2009 May;19(5):1206-13. doi: 10.1007/s00330-008-1258-5. Epub 2009 Jan 10.

Abstract

There is little published long-term survival data for patients with colorectal liver metastases treated with radiofrequency ablation (RFA). We present a multivariate analysis of 5-year survival in 309 patients (198 male, aged 64 (24-92)) treated at 617 sessions. Our standard protocol used internally cooled electrodes introduced percutaneously under combined US and CT guidance/monitoring. The number and size of liver metastases, the presence and location of extrahepatic disease, primary resection, clinical, chemotherapy and follow-up data were recorded. Data analysis was performed using SPSS v.10. On multivariate analysis, significant survival factors were the presence of extrahepatic disease (p < 0.001) and liver tumour volume (p = 0.001). For 123 patients with five or less metastases of 5 cm or less maximum diameter and no extrahepatic disease median survival was 46 and 36 months from liver metastasis diagnosis and ablation, respectively; corresponding 3- and 5-year survival rates were 63%, 34% and 49%, 24%. Sixty-nine patients had three or less tumours of below 3.5 cm in diameter and their 5-year survival from ablation was 33%. There were 23/617(3.7%) local complications requiring intervention. Five-year survival of 24-33% post ablation in selected patients is superior to any published chemotherapy data and approaches the results of liver resection.

摘要

关于接受射频消融(RFA)治疗的结直肠癌肝转移患者,已发表的长期生存数据很少。我们对309例患者(198例男性,年龄64岁(24 - 92岁))在617次治疗中的5年生存率进行了多变量分析。我们的标准方案是在超声和CT联合引导/监测下经皮插入内部冷却电极。记录肝转移灶的数量和大小、肝外疾病的存在和位置、原发灶切除情况、临床、化疗及随访数据。使用SPSS v.10进行数据分析。多变量分析显示,显著的生存因素为肝外疾病的存在(p < 0.001)和肝肿瘤体积(p = 0.001)。对于123例最大直径5 cm及以下转移灶数量为5个或更少且无肝外疾病的患者,自肝转移诊断和消融起的中位生存期分别为46个月和36个月;相应的3年和5年生存率分别为63%、34%和49%、24%。69例患者有3个或更少直径小于3.5 cm的肿瘤,其消融后的5年生存率为33%。617例中有23例(3.7%)出现需要干预的局部并发症。在选定患者中,消融后24% - 33%的5年生存率优于任何已发表的化疗数据,接近肝切除术的结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验